Abstract
Glucagon-like peptide-1 (GLP-1) is a polypeptide incretin hormone that glucose-dependently promotes the secretion and synthesis of insulin. However, its half-life is extremely short. To enhance its half-life, we developed a long-acting GLP-1 derivative KTP with controlled release, designed on the basis of another GLP-1 derivative GP62. The kinetics and bioactivity of KTP were evaluated in Sprague Dawley (SD) rats. Long-term treatment of KTP was performed in db/db mice. Mice were treated twice daily with subcutaneous injections of KTP (1.2 mg/kg body weight), Exendin-4 (0.1 mg/kg body weight) or vehicle (phosphate buffered saline (PBS), pH 7.4) for 60 d. KTP had a longer half-life, as well as further increasing the secretion and production of insulin and reducing blood glucose concentrations, than GP62. Long-term treatment with KTP also induced anorexia, decreased water and food intake, decreased weight gain, improved blood glucose and blood lipid and ameliorated pancreatic damage and fatty liver in db/db mice.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ørskov C. Glucagon-like peptide-1, a new hormone of the stimula-entero-insular axis. Diabetologia, 1992, 35: 701–711
Fehmann H C, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr Rev, 1995, 16: 390–410
Holz G G, Kuhtreiber W M, Habener J F. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7–37). Nature, 1993, 361: 362–365
Holst J J, Ørskov C, Nielsen O V, et al. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett, 1987, 211: 169–174
Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Rel Metab Disord, 1999, 68: 304–311
Naslund E, Gutniak M, Skogar S, et al. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr, 1998, 23: 525–530
Edvell A, Lindstrom P. Initiation of increased pancreatic islet growth in young normoglycemic mice. Endocrinology, 1999, 140: 778–783
Gutniak M, Ørskov C, Holst J J, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. New Engl J Med, 1992, 326: 1316–1322
Gutniak M K, Linde B, Holst J J, et al. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care, 1994, 17: 1039–1044
Nauck M A, Kleine N, Ørskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 1993, 36: 741–744
Nauck M A, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia, 1996, 39: 1546–1553
Nauck M A, Sauerwald A, Ritzel R, et al. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care, 1998, 21: 1925–1931
Qualmann C, Nauck M A, Holst J J, et al. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7–36 amide] in the fasting state in healthy subjects. Acta Diabetol, 1995, 32: 13–16
Toft-Nielsen M B, Madsbad S, Holst J J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care, 1999, 22: 1137–1143
Mentlein R, Gallwitz B, Schmidt W E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7–36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem, 1993, 214: 829–835
Kieffer T J, McIntosh C H, Pederson R A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 1995, 136: 3585–3596
Kumar M D, Baboota S, Ahuja A, et al. Recent advances in protein and peptide drug delivery systems. Drug Delivery, 2007, 4: 141–151
Pawar R, Ben Ari A, Domb A J. Protein and peptide parenteral controlled delivery. Expert Opin Biol Ther, 2004, 4: 1203–1212
Li H J, Ma Y, Chen Y, et al. A protease-based strategy for the controlled release of therapeutic peptides. Angew Chem Int Ed Engl, 2010, 49: 4930–4933
Marques C M M, Motta V F, Torres T S, et al. Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. Braz J Med Biol Res, 2010, 43: 467–475
Julio C F, Rebeca O D, Caroline F S, et al. A mouse model of metabolic syndrome: Insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr, 2010, 46: 212–223
Su Z, Vinogradova A, Koutychenko A, et al. Rational design and selection of bivalent peptide ligands of thrombin incorporating P4-P1 tetrapeptide sequences: from good substrates to potent inhibitors. Protein Eng Des Sel, 2004, 17: 647–657
Alberto D T, Carlos G A, Silvia C, et al. Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs. J Med Chem, 2010, 53: 559–572
Turton M D, O’Shea D O, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature, 1996, 379: 69–72
Larsen P J, Fledelius C, Knudsen L B, et al. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes, 2001, 50: 2530–2539
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Sang, Y., Zhou, T., Li, H. et al. A new long-acting GLP-1 derivative KTP ameliorates hyperglycemia and dyslipidemia and improves pancreas and fatty liver in db/db mice. Chin. Sci. Bull. 58, 2447–2453 (2013). https://doi.org/10.1007/s11434-013-5915-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11434-013-5915-y